In the last trading session, 5.62 million Agenus Inc (NASDAQ:AGEN) shares changed hands as the company’s beta touched 1.31. With the company’s per share price at $0.69 changed hands at -$0.01 or -1.43% during last session, the market valuation stood at $263.23M. AGEN’s last price was a discount, traded about -371.01% off its 52-week high of $3.25. The share price had its 52-week low at $0.61, which suggests the last value was 11.59% up since then. When we look at Agenus Inc’s average trading volume, we note the 10-day average is 9.9 million shares, with the 3-month average coming to 5.74 million.
Analysts gave the Agenus Inc (AGEN) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended AGEN as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Agenus Inc’s EPS for the current quarter is expected to be -$0.05.
Agenus Inc (NASDAQ:AGEN) trade information
Instantly AGEN was in red as seen at the end of in last trading. With action 6.14%, the performance over the past five days has been green. The drop to weekly highs of 0.7949 on Friday, 11/17/23 subtracted -1.43% to the stock’s daily price. The company’s shares are showing year-to-date downside of -70.70%, with the 5-day performance at 6.14% in the green. However, in the 30-day time frame, Agenus Inc (NASDAQ:AGEN) is -28.35% down. Looking at the short shares, we see there were 34.18 million shares sold at short interest cover period of 6.63 days.
The consensus price target for the stock as assigned by Wall Street analysts is $6.50, meaning bulls need an upside of 89.38% from its current market value. According to analyst projections, AGEN’s forecast low is $6.00 with $8.00 as the target high. To hit the forecast high, the stock’s price needs a -1059.42% plunge from its current level, while the stock would need to soar -769.57% for it to hit the projected low.
Agenus Inc (AGEN) estimates and forecasts
Data shows that the Agenus Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -50.71% over the past 6 months, a 19.23% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Agenus Inc will rise 79.20%, while the growth in revenue is estimated to hit 31.80% for the next quarter. Year-over-year growth is forecast to reach 21.30% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of $47.05 million. The company’s revenue for the corresponding quarters a year ago was $28.39 million. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 65.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.66%. The 2023 estimates are for Agenus Inc earnings to increase by 16.91%.
Agenus Inc is expected to release its next quarterly earnings report on November 07.
Agenus Inc (NASDAQ:AGEN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.45% of Agenus Inc shares while 60.95% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 65.86%. There are 60.95% institutions holding the Agenus Inc stock share, with Deep Track Capital, Lp the top institutional holder. As of Sep 29, 2023, the company held 8.31% of the shares, roughly 31.7 million AGEN shares worth $21.87 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 7.44% or 28.39 million shares worth $19.59 million as of Sep 29, 2023.
Among Mutual Funds, the top two as of Sep 29, 2023 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. With 13.34 million shares estimated at $9.2 million under it, the former controlled 3.50% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.45% of the shares, roughly 9.35 million shares worth around $6.45 million.